<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899130</url>
  </required_header>
  <id_info>
    <org_study_id>OI- 002- 2016</org_study_id>
    <nct_id>NCT02899130</nct_id>
  </id_info>
  <brief_title>Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus</brief_title>
  <official_title>Antiviral Effect of 3 Herbs in Chronic Inactive Carriers of Hepatitis B Virus. - A Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organic India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organic India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the effect of a polyherbal capsule in lowering the viral load of
      patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B
      surface antigen elimination in 12 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo controlled randomised trial. 3 herbs that have proven effect on eliminating the
      virus and normalizing liver function will be given. Equally matched placebo (blinded) will be
      given randomly to patients. All parameters of hepatitis B infection will be compared between
      the randomized groups
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with change in hepatitis B surface antigen titers from baseline for those with HBV DNA &lt;1000 IU/ml</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Incidence of seroconversion from Hepatitis B surface antigen to anti-Hepatitis B surface antibody</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Polyherbal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of 3 whole herbs in a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar looking inert capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyherbal</intervention_name>
    <description>Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa</description>
    <arm_group_label>Polyherbal</arm_group_label>
    <other_name>Liver Kidney Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive compound that is similar looking as the intervention</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged above 18 years of age, with inactive chronic hepatitis B (HB) or immune
             tolerant phase, with or without dyslipidaemia and having all of the following

               1. HBsAg +ve for &gt;6 months and anti-HBs negative

               2. Alanine amino transferase ≤ 2 upper limit of normal

               3. HBeAg positive or negative irrespective of viral DNA load

               4. Not currently on antiviral therapy for Chronic hepatitis B

        Exclusion Criteria:

          -  Any one of the following

               1. Patients with decompensated liver disease of any etiology(characterized by
                  elevated bilirubin, raised International normalized ratio, or a history of
                  ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial
                  peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)

               2. Family history of hepatocellular carcinoma

               3. Patients with HIV and Hepatitis C virus co-morbidity

               4. Pregnant, attempting to conceive, or lactating women

               5. Patients with diabetes mellitus

               6. Recent history of acute coronary syndrome (&lt;6months) or chronic coronary artery
                  disease with poor left ventricular function (by physician / cardiology opinion)

               7. Patients with renal failure ( Creatinine clearance less than 60 ml/min)

               8. Active substance or alcohol abuse and concurrent use of corticosteroids or
                  immunosuppressive agents.

               9. Presence of extra hepatic manifestations

              10. Previously treated with pegylated interferon within the last 2 years

              11. Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3
                  and above)

              12. Current or former employees of organic India

              13. Participating in another clinical trial with an active intervention or drug or
                  device with last dose taken within 60 days.

              14. Refusing consent or physician uncomfortable with patient compliance to treatments
                  or follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alben Sigamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Narayana Hrudayalaya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alben Sigamani, MD</last_name>
    <phone>+91 8884431444</phone>
    <email>alben.sigamani.dr@nhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjaya Chauhan, Pharm.D</last_name>
    <phone>+91 9611252350</phone>
    <phone_ext>2388</phone_ext>
    <email>drsanjayachauhan49@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mazumdar Shaw Mutispeciality Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alben Sigamani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

